Tobevibart, elebsiran combination shows promise in hepatitis D virus infection The combination of tobevibart and elebsiran has the potential to tackle chronic HDV infections, the ongoing phase 2 SOLSTICE trial finds.

#MedNews - The combination of #tobevibart and #elebsiran has the potential to tackle chronic #HDV infections, the ongoing phase 2 SOLSTICE trial finds.

Full story 👉 buff.ly/I8DQxT7

#IDSky

Weekly Roundup - PHARMA - 16 December 2024 🔊AstraZeneca's Imfinzi Wins FDA Approval for Limited-Stage Small Cell Lung Cancer AstraZeneca's Imfinzi offers a new post-chemotherapy immunotherapy. The ADRIATIC trial showed survival benefits, makin...

Weekly Roundup - PHARMA - 16 December 2024

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#AstraZeneca #Imfinzi #Govorestat #Ozempic #Delgocitinib #SaudiArabia #GenScript #Tobevibart #Elebsiran #NeuroSense #PrimeC #Humanteconomy #Humantec #KStrategyand